Regulus Therapeutics Inc. (RGLS) announced after the bell Monday that it has received verbal notification from the FDA that RG-101 has been placed on clinical hold. The treatment for chronic hepatitis C virus infection was put on hold after Regulus reported a second serious adverse event of jaundice.
from RTT - Before the Bell http://ift.tt/29a9w08
via IFTTT
No comments:
Post a Comment